Best of ASCO - 2014 Annual Meeting



Ovarian Cancer

Gynecologic Cancer

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
A 3D micro-tumor model capturing tumor heterogeneity of a patient's primary tumor biopsy.

Katya Nikolov


A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial.

Deborah Kay Armstrong


A phase I trial evaluating the safety and efficacy of weekly paclitaxel or cisplatin with electro-hyperthermia in patients with recurrent or persistent epithelial ovarian, fallopian tubal or primary peritoneal carcinoma (KGOG 3030).

Kidong Kim


A phase II randomized study of avelumab plus entinostat versus avelumab plus placebo in patients (pts) with advanced epithelial ovarian cancer (EOC).

Karen Anne Cadoo


A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia.

Stephanie Lheureux


A randomized, double-blind, placebo-controlled phase Ib/II study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine (G) and carboplatin (C) versus GC for women with recurrent platinum-sensitive ovarian cancer.

Ignace Vergote


A retrospective review on extended carboplatin infusion and incidence of hypersensitivity reaction in gynecologic malignancies in a single institution.

Jennifer Park


Accuracy of primary laparoscopic staging in patients with early ovarian malignancies: A retrospective multicenter study.

Julia Caroline Radosa


Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.

Kathleen N. Moore


Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.

Nicoletta Colombo


AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC).

Frederik Marme


An optimized homologous recombination deficiency (HRD) algorithm ASGAD for predicting PARP inhibitor response in ovarian cancer patient.

Yang Jiao


ARID1A interacts with nonmuscle myosin IIA to regulate cancer cell motility.

Oloruntoba Ismail Osagie


Association between time to first subsequent therapy (TFST) and overall survival (OS) in previously untreated patients with ovarian cancer (OC): A SEER Medicare database analysis.

Kaushal Desai


Association of Ki67 expression levels and therapy outcome in low-grade serous ovarian cancer.

J.P. P. Grabowski


Bevacizumab beyond progression: Impact of subsequent bevacizumab retreatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.

Rebecca Ann Previs


Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer (rOC)? A network meta-analysis (NMA).

Michele Bartoletti


Bovine milk-derived exosomes mediated delivery of resibufogenin and its effect on platinum-resistant ovarian carcinoma.

Guannan Zhou


BRCA tumor test in ovarian cancers: The changing role of molecular pathology in the era of PARP inhibitor (PARPi) therapy.

Caterina Fumagalli


CD49d (high) T cells in the ovarian cancer microenvironment are a potential target for the optimization of immune checkpoint therapy in ovarian cancer.

Henning De May


Circulating tumor DNA analysis to reveal genomic profiles for epithelial ovarian cancer.

Yang Xiang


Clinical benefit of bevacizumab in Mexican ovarian cancer patients according to the intention of treatment by the oncologist.

Dolores Gallardo-Rincon


Clinical characteristics of clear cell ovarian cancer: A retrospective multicenter experience of 308 patients in South Korea.

Hee Yeon Lee


Clinical outcome of sequential chemotherapy after immune checkpoint inhibitors in advanced ovarian cancer.

Luisa Bonilla


Clinical outcomes of postoperative intraperitoneal chemotherapy for patients with early-stage high-grade serous ovarian cancer (HGSC) treated at British Columbia cancer agency.

Joohyun Lee


Clinicopathologic features and prognostic analysis of stage I ovarian clear cell cancer.

Tian Tian Wang


Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24.

Mansoor Raza Mirza


Comprehensive genomic analysis of mucinous ovarian cancer reveals unique therapeutic vulnerabilities.

Dane Anthony Cheasley


Correlation of surgeon radiology assessment with laparoscopic scoring in patients with advanced-stage ovarian cancer.

Nicole D. Fleming


Cost-effectiveness analysis of laparoscopic disease assessment in ovarian cancer.

Ross Harrison


Delay in time to adjuvant chemotherapy and its impact on outcome in completely resected advanced ovarian malignancies treated with CRS, CRS+IP and CRS +HIPEC.

Ashwin K Rajgopal


Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer.

Ying L Liu


Dose-dense early postoperative intraperitoneal chemotherapy in ovarian cancer: Randomized, phase II trial.

Rongyu Zang


DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE1 trial): T cell responses and tumor infiltration correlate with tumor regression.

Janos Laszlo Tanyi


DUO-O: A randomized Phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.

Philipp Harter


Dynamic of molecular subtypes of high‐grade serous ovarian cancer in paired primary and relapsed biopsies.

Elena Ioana Braicu


E-consult: To better inform patient.

Jean-Francois LE Brun


Effect of estrogen and progesterone receptor expression on progression-free and overall survival outcomes in low-grade serous ovarian cancer.

Marta Llaurado Fernandez


Effects of bevacizmab, eribulin and oxaliplatin in relapsed patients with platinum-resistant and refractory ovarian carcinomas: A preliminary case series with biomarker evaluation.

Jin Suminokura


Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.

Wendy M Swetzig


Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.

Michael Friedlander


Elucidation of PARP inhibitor activity in BRCAwt recurrent ovarian cancer by hrr mutational gene profile analysis.

Mansoor Raza Mirza


ENGOT-Ov41/GEICO-69-O/ANITA trial: A phase III randomized, double-blinded trial of platinum-based chemotherapy (CT) with or without atezolizumab (ATZ) followed by niraparib maintenance with or without ATZ in patients with recurrent ovarian, tubal or peritoneal cancer (OC) and platinum treatment-free interval (TFIp) >6 months.

Antonio González-Martín


ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.

Ignace Vergote


ENGOT-OV44/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC).

Anne-Claire Hardy-Bessard


EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the HSP90 inhibitor ganetespib with carboplatin followed by maintenance treatment with niraparib (+/- ganetespib) compared to platinum-based combination-chemotherapy followed by niraparib in relapsed platinum-sensitive ovarian cancer patients.

Nicole Concin


Everolimus plus letrozole treatment of recurrent gynecologic cancers.

Kenneth David Miller


Evolve: A post PARP inhibitor clinical translational phase II trial of cediranib-olaparib in ovarian cancer—A Princess Margaret Consortium – GCIG Phase II Trial.

Stephanie Lheureux


EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study.

Claire Falandry


Exploratory analysis of the effect of maintenance rucaparib on postprogression outcomes in patients (pts) with platinum-sensitive recurrent ovarian carcinoma (OC) and updated safety data from the phase 3 study ARIEL3.

Robert L. Coleman


Exploring racial disparities of actionable mutations in gynecologic cancers.

Vasanti Jhaveri


Factors associated with extended survival for patients with platinum-resistant ovarian cancer treated with modified vaccinia oncolytic virotherapy.

Madhavi Manyam


Factors associated with one-year mortality after debulking surgery in older women with ovarian cancer.

Olga T. Filippova


First-in-human (FIH) phase 1 (Ph1) study of MORAb-202 in patients (pts) with advanced folate receptor alpha (FRA)-positive solid tumors.

Toshio Shimizu


FLABRA, frontline approach for BRCA testing in ovarian cancer (OC) treatment naïve population: A Latin America (LA) epidemiologic study.

Susana Beatriz Goncalves


Glucocorticoid receptor expression in Müllerian carcinosarcomas.

Meghan Steiner


GPR30 signaling to regulate epithelial-mesenchymal transition and predict survival in ovarian cancer.

Satoe Fujiwara


Half-dose olaparib reduction: Safe and efficient dose in multi-treated Mexican ovarian cancer patients.

Dolores Gallardo-Rincon


How do we bridge the gap? persistent differences in the preoperative experience for patients with gynecologic cancer treated at a public hospital.

Deanna Gerber


How long have we got? The accuracy of physicians’ estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC).

Felicia Roncolato


Hypermetabolic activity by FDG-PET after immunogenic chemotherapy and multi-peptide immunotherapy in ovarian cancer.

Juan Pablo Marquez-Manriquez


Identification of prognostic variables in advanced ovarian cancer based on real-world patients from big data analytics.

Jesús García-Donas


Impact of a structured quality management program on survival of patients with advanced (AOC) and relapsed ovarian cancer (ROC) treated in a dedicated tertiary gynecologic-oncology (GO) center.

Philipp Harter


Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.

Gwenael Ferron


Impact of BRCA mutation status and time to platinum resistance on patients with advanced ovarian cancer.

Alexandra Tyulyandina


Impact of the Affordable Care Act on early-stage diagnosis and treatment for women with ovarian cancer.

Anna Jo Smith


Incorporation of HIPEC into a high volume ovarian cancer program: Initial results and outcomes.

Aliza L. Leiser


Increasing potency and safety of anticancer drugs through sortilin receptor-mediated cancer therapy: A new targeted approach for the treatment of ovarian cancer.

Borhane Annabi


Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.

Cara Amanda Mathews


Menopausal symptoms in epithelial ovarian cancer survivors: The GINECO VIVROVAIRE2 study.

Florence Joly


Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study.

David M. O'Malley


Modeled CA-125 kinetics during neoadjuvant chemotherapy for predicting the likelihood of optimal interval debulking surgery in ovarian cancer patients: Data from CHIVA trial (a GINECO study).

Patrick Robelin


Molecular stratification of endometrioid ovarian carcinomas.

Barbara Stanley


Multi-parametric FDG PET/MRI as an early predictor of response to neoadjuvant chemotherapy in patients with epithelial ovarian cancer.

Melissa Kristen Frey


Multiple genetic alterations to predict the clinical outcome for bevacizumab plus chemotherapy in advanced ovarian cancer: A retrospective study.

Nan Du


Mutational landscape of ovarian cancers (OC) identified by prospective clinical sequencing in a nationwide cancer network.

Julian Schink


Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: An institutional experience.

Kavitha Jain


New biomarkers to predict platinum resistance in ovarian cancer patients.

Oana Trifanescu


Ofranergene obadenovec (VB-111) in platinum resistant ovarian cancer: with an immunotherapeutic effect.

Yael Chava Cohen


Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort.

Lingying Wu


Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.

Richard T. Penson


Omission of adjuvant therapy in stage I clear cell ovarian cancer: Review of the British Columbia (BC) cancer experience.

Shiru Lucy Liu


Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis.

Genevieve Bouchard-Fortier


Patient preferences for maintenance PARP therapy in ovarian cancer treatment.

Laura Jean Havrilesky


Pembrolizumab with low dose carboplatin for recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer-interim results.

John B. Liao


Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208).

Haider Mahdi


Phase I (safety assessment) of durvalumab (MEDI4736) with focal sensitizing radiotherapy in platinum resistant ovarian, primary peritoneal or fallopian tube epithelial carcinoma.

Anna Tinker


Phase Ib clinical investigation of intraperitoneal ipilimumab and nivolumab in patients with peritoneal carcinomatosis due to gynecologic malignancy.

Emily Hinchcliff


Poly adenosine diphosphate ribose polymerase inhibitors maintenance in patients with ovarian cancer: A systematic review and meta-analysis of randomized controlled trials.

Thura WIN Htut


Predictive factors of cytoreductive surgery in epithelial ovarian cancer in a Mexican women cohort.

Flavia Morales Vasquez


Prognosis of ovarian cancer in the United States during 1973 to 2015.

Jianfeng Zhang


Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery.

Laura Vincent


Prognostic implications of lymph node metastasis in advanced ovarian cancer: Analysis of the National Cancer Database 2006 to 2014.

Mohamed Elgamal


Prognostic value of monocyte to lymphocyte ratio (MLR) in epithelial ovarian cancer (EOC).

Marc Cucurull


Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer.

Adriaan Vanderstichele


Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) 50 mg/m2 and 40 mg/m2 in patients with platinum-resistant Müllerian carcinoma (JGOG3018).

Akira Yabuno


Real life efficacy and safety data of bevacizumab-based front line treatment in advance or metastatic ovarian cancer patients: Focus on patients with malignant ascites—A phase IV study.

Michail Nikolaou


Real time FTIR spectroscopy of tissue smears from gynecologic cancer tissues: A preliminary study.

Ilan Bruchim


Real-life data: Women with recurrent platinum-sensitive ovarian cancer and BCARGEM treatment.

Frederique C. van der Scheun


Real-world bevacizumab utilization and outcomes in first-line ovarian cancer.

Matthew J. Monberg


Real-world data analysis of ovarian cancer (OC) maintenance utilization among maintenance eligible patients.

David Garofalo


Real-world duration of maintenance therapy in 2nd-line and later ovarian cancer (OC).

David Garofalo


Recurrence of ovarian cancer in BRCAwt patients without maintenance therapy: Real-world evidence.

Melinda Louie-Gao


Results of the VENUS study: Bevacizumab efficacy and safety in platinum-sensitive recurrent ovarian cancer (OC)—A real-life ambispective study.

Isabelle Laure Ray-Coquard


Rethinking breast cancer surveillance in women with BRCA-associated ovarian cancer in the post-solo trial era.

Catherine S. John


Risk factors for progression or death in ovarian cancer patients who completed first-line platinum treatment.

Shannon Neville Westin


Sarcopenia as a predictor of chemotherapy toxicity in patients with ovarian cancer receiving platinum and taxane-based chemotherapy.

Katherine Tucker


Sarcopenia as a predictor of survival in patients with epithelial ovarian cancer (EOC) receiving platinum and taxane-based chemotherapy.

Stuart-Allison Moffat Staley


Selective and nonselective GR antagonists in combination with chemotherapy in ovarian cancer PDX models.

Jennifer Taylor Veneris


Serum calretinin as a predictor for recurrence and overall survival in ovarian cancer.

Pauline Wimberger


SOLO1 versus SOLO2: Cost-effectiveness of olaparib as maintenance therapy for newly diagnosed and platinum-sensitive recurrent ovarian carcinoma among women with germline BRCA mutations (gBRCAmut).

Juliet Elizabeth Wolford


Surveillance in stage I MOGCTs (malignant ovarian germ cell tumors): A MITO prospective study (multicenter Italian trials in ovarian cancer).

Alice Bergamini


Survival and clinical outcomes of ovarian cancer patients enrolled in phase I clinical trials.

Bradley Corr


T cell trafficking within the peritoneal tumor environment and ovarian cancer progression.

Sharina Palencia Desai


Telomere length and its implication as prognostic marker in ovarian cancer patients.

David M. Atallah


The association of marital status, socioeconomic status, and race on the survival of ovarian cancer patients.

Austin Blake Gardner


The Circulating Cell-free Genome Atlas (CCGA) Study: Follow-up (F/U) on non-cancer participants with cancer-like cell-free DNA signals.

Allen Lee Cohn


The developmental origins of high grade serous ovarian cancer.

Pietro Lo Riso


The effects of Wnt inhibition on tumor progression and the tumor microenvironment in a syngeneic mouse model of ovarian cancer.

Whitney Goldsberry


The prognosis of patients with recurrent or persistent ovarian clear cell carcinoma: Results from a randomized phase III study (JGOG3017/GCIG).

Eiji Kondo


The role of macrophage production of transforming growth factor-ß in epithelial ovarian cancer progression.

Brandon Roane


Tumor stroma proportion to predict platinum chemoresistance in primary ovarian carcinomas: A prospective study.

Emil Lou


Visceral adiposity as a predictor of survival in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy.

Stuart-Allison Moffat Staley